These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36271897)

  • 21. The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective.
    George JN
    Blood Adv; 2018 Jun; 2(12):1510-1516. PubMed ID: 29945940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura.
    Patriquin CJ; Thomas MR; Dutt T; McGuckin S; Blombery PA; Cranfield T; Westwood JP; Scully M
    Br J Haematol; 2016 Jun; 173(5):779-85. PubMed ID: 27009919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune-mediated thrombotic thrombocytopenic purpura.
    Stubbs MJ; Low R; McGuckin S; Newton R; Thomas M; Westwood JP; Shah R; Cheesman S; Scully MA
    Br J Haematol; 2019 Jun; 185(5):912-917. PubMed ID: 30919938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura.
    Sui J; Cao W; Halkidis K; Abdelgawwad MS; Kocher NK; Guillory B; Williams LA; Gangaraju R; Marques MB; Zheng XL
    Blood Adv; 2019 Dec; 3(24):4177-4186. PubMed ID: 31856267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura.
    Roose E; Schelpe AS; Tellier E; Sinkovits G; Joly BS; Dekimpe C; Kaplanski G; Le Besnerais M; Mancini I; Falter T; Von Auer C; Feys HB; Reti M; Rossmann H; Vandenbulcke A; Pareyn I; Voorberg J; Greinacher A; Benhamou Y; Deckmyn H; Fijnheer R; Prohászka Z; Peyvandi F; Lämmle B; Coppo P; De Meyer SF; Veyradier A; Vanhoorelbeke K
    Blood; 2020 Jul; 136(3):353-361. PubMed ID: 32356859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune-mediated thrombotic thrombocytopenic purpura in patients with and without systemic lupus erythematosus: a retrospective study.
    Yue C; Su J; Fan X; Song L; Jiang W; Xia J; Shi T; Zhang X; Li X
    Orphanet J Rare Dis; 2020 Aug; 15(1):225. PubMed ID: 32859237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature.
    Yilmaz M; Eskazan AE; Unsal A; Taninmis H; Kara E; Cetiner M; Ferhanoglu B
    Transfusion; 2013 Jul; 53(7):1586-93. PubMed ID: 23121663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of immune-mediated thrombotic thrombocytopenic purpura: A decisive turning point].
    Poullin P
    Transfus Clin Biol; 2021 Nov; 28(4):380-385. PubMed ID: 34464709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura.
    Ferrari S; Palavra K; Gruber B; Kremer Hovinga JA; Knöbl P; Caron C; Cromwell C; Aledort L; Plaimauer B; Turecek PL; Rottensteiner H; Scheiflinger F
    Haematologica; 2014 Apr; 99(4):779-87. PubMed ID: 24241492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab.
    Zheng X; Pallera AM; Goodnough LT; Sadler JE; Blinder MA
    Ann Intern Med; 2003 Jan; 138(2):105-8. PubMed ID: 12529092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity.
    Cataland SR; Jin M; Lin S; Kennedy MS; Kraut EH; George JN; Wu HM
    Br J Haematol; 2007 Nov; 139(3):486-93. PubMed ID: 17910638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Successful rituximab treatment in an elderly patient with recurrent thrombotic thrombocytopenic purpura].
    Matsubara E; Yamanouchi J; Hato T; Takeuchi K; Niiya T; Yasukawa M
    Rinsho Ketsueki; 2016 Jul; 57(7):869-72. PubMed ID: 27498731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombotic thrombocytopenic purpura.
    Joly BS; Coppo P; Veyradier A
    Blood; 2017 May; 129(21):2836-2846. PubMed ID: 28416507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura.
    Chen H; Fu A; Wang J; Wu T; Li Z; Tang J; Shen H; Zhu J; Li J; Zhu Q; Qing L
    J Int Med Res; 2017 Jun; 45(3):1253-1260. PubMed ID: 28639502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura.
    Roose E; Vidarsson G; Kangro K; Verhagen OJHM; Mancini I; Desender L; Pareyn I; Vandeputte N; Vandenbulcke A; Vendramin C; Schelpe AS; Voorberg J; Azerad MA; Gilardin L; Scully M; Dierickx D; Deckmyn H; De Meyer SF; Peyvandi F; Vanhoorelbeke K
    Thromb Haemost; 2018 Oct; 118(10):1729-1742. PubMed ID: 30235483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complete ADAMTS13 remission in a patient with refractory autoimmune-mediated thrombotic thrombocytopenic purpura after infliximab.
    Bavli N; Lee N; Sarode R; Burstein E; Rambally S
    Transfus Apher Sci; 2021 Dec; 60(6):103213. PubMed ID: 34400095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI).
    Cid J; Pérez-Valencia AI; Torrente MÁ; Ávarez-Larrán A; Díaz-Ricart M; Esteve J; Lozano M
    Transfus Apher Sci; 2021 Feb; 60(1):103011. PubMed ID: 33221124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of autoimmune thrombotic thrombocytopenic purpura in the more severe forms.
    Coppo P;
    Transfus Apher Sci; 2017 Feb; 56(1):52-56. PubMed ID: 28110841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.
    Mariotte E; Azoulay E; Galicier L; Rondeau E; Zouiti F; Boisseau P; Poullin P; de Maistre E; Provôt F; Delmas Y; Perez P; Benhamou Y; Stepanian A; Coppo P; Veyradier A;
    Lancet Haematol; 2016 May; 3(5):e237-45. PubMed ID: 27132698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging roles of adjunct therapies in acquired thrombotic thrombocytopenia purpura.
    Racine-Brzostek SE; Shi PA
    Transfusion; 2019 Aug; 59(8):2496-2498. PubMed ID: 31283011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.